Your life sciences deals slip after the verbal yes.

Selling software to a biopharma or medtech company typically takes 6–18 months, by our estimate, and the segment matters more than the product. Clinical-stage biotechs decide in an estimated 1–9 months, established medtech makers and CROs in 3–12 months and mid-size pharma in 4–18 months. Enterprise platforms at top-tier biopharma take an estimated 6–24 months, and GxP supplier qualification can add an estimated 2–6 months.

The buying group for GxP software at a biopharma or medtech company is led by the function head who owns the budget, often in quality, clinical operations, regulatory or safety. IT, computerised system validation, information security, legal and finance can each veto. Process owners shape the choice, and validation consultants or CROs often influence the shortlist. By our estimate, the group has 5–12 people, or 3–5 people at a small biotech or medtech firm.

A software vendor gets on a big pharma preferred vendor list by signing an MSA and a quality agreement before a project needs them. It also has to pass GxP supplier qualification, which a SOC 2 report does not replace, to join the approved supplier list. Large biopharma companies are consolidating suppliers and tend to give new work to vendors already approved. Build a relationship with category management early, and pick a niche, such as a therapy area, modality or region, where a specialist can win.

GxP supplier qualification of a software vendor at a biopharma or medtech company takes an estimated 2–6 months. QA runs a risk-based supplier assessment, often with a remote or on-site audit, while security reviews SOC 2 Type II and ISO 27001 evidence. A SOC 2 report does not replace the audit. Opening qualification at the first meeting lets it run alongside the evaluation instead of after the verbal yes.

The strongest buying signals at biotech companies are a financing round that names a trial start and a move from Phase 2 to Phase 3. A filing or PDUFA date, an acquisition and a new clinical, quality or regulatory leader open windows too. Trial registration is a late signal: US rules allow up to 21 days after the first participant enrols, by which time the CRO and systems are chosen. Record each signal as a dated field on the account.

Larger pharma and medtech companies tend to set next year’s IT and quality budgets in Q3 and Q4, by our estimate. Pharma brand plans run from late spring to autumn, while biotech budgets follow financing rounds and trial starts. A need found late in the year without a funded line usually waits for the next cycle. Record each account’s budget window on the opportunity.

Life sciences webinars and downloads often reach scientists, students and academics who hold no budget, and interest arrives months before money does. Counting individuals hides which biopharma and medtech accounts are engaged. Qualify accounts instead: fit with your closed-won customers plus engagement from more than one role in the buying group, such as quality and IT together. Then separate engagement metrics from sales activation in your CRM.

Software vendors multi-thread biopharma and medtech deals by mapping every seat that can veto at the first meeting. Those seats are usually QA, IT, computerised system validation, security, legal and finance. They open GxP supplier qualification at the same time and give each role the evidence it asks for. They then track the roles engaged on each open deal against a baseline, so gaps show before the shortlist forms.